Skip to main contentSkip to main content

You are the owner of this article.

Edit Article Add New Article Close

You have permission to edit this article.

Edit Close

JournalStar.com

39°

Read Today's E-edition

Site Search

© 2026 Lee Enterprises

Terms of Service | Privacy Policy

Site Search

JournalStar.com

News+

Where your story lives

Site Search

A Lee Enterprises, Incorporated newspaper. Majority shareholder: David Hoffmann, Hoffmann Media Group.

Subscribe

Read Today's E-edition

JournalStar.com

News+

Where your story lives

Subscribe

Share This

Watch Now: Risk dial moves to green as COVID-19 continues to loosen grip on Lincoln

0 Comments

Share this

A Lee Enterprises, Incorporated newspaper. Majority shareholder: David Hoffmann, Hoffmann Media Group.

Editor's Pick Alert Top Story

Watch Now: Risk dial moves to green as COVID-19 continues to loosen grip on Lincoln

Prefer us on Google Learn More

March 22, 2022, COVID-19 update

kAmp 4@?E:?F65[ DFDE2:?65 5C@A :? r~'xs\`h 42D6D 92D >@G65 E96 =@42= C:D< 5:2= E@ 2 A=246 :EVD C2C6=J 366? 5FC:?8 E96 A2?56>:4i 8C66?]k^Am

kAm{:?4@=?\{2?42DE6C r@F?EJ w62=E9 s:C64E@C !2E {@A6K @? %F6D52J D2:5 E96 =@42= D:EF2E:@? 92D :>AC@G65 6?@F89 E@ ;FDE:7J >@G:?8 E96 5:2= E@ E96 8C66? C2?86[ H9:49 C6AC6D6?ED 2 =@H C:D< @7 E96 DAC625 @7 E96 5:D62D6]k^Am

kAmQ~FC =@42= :?5:42E@CD 92G6 5C@AA65 C2A:5=J[Q {@A6K D2:5[ ?@E:?8 E92E E96 C:D< 5:2= H2D :? E96 C65 C2?86[ @C D6G6C6[ 2D C646?E=J 2D 62C=J u63CF2CJ]k^Am

kAm{2DE H66<[ {2?42DE6C r@F?EJ C64@C565 @?=J gh r~'xs\`h 42D6D[ E96 =@H6DE H66<=J E@E2= D:?46 yF=J a] %96 E6DE A@D:E:G:EJ C2E6 2=D@ H2D 2E :ED =@H6DE =6G6= D:?46 yF=J a_a` 2?5 92D ?@H 366? 36=@H dT 7@C E9C66 H66<D :? 2 C@H]k^Am

People are also reading…

Lopez

JUSTIN WAN, Journal Star file photo

kAm(66<=J 42D6D 92G6 564=:?65 >@C6 E92? hgT D:?46 9:EE:?8 2 A2?56>:4 9:89 @7 c[he` E96 H66< 6?5:?8 y2?] `d]k^Am

kAm%96 5C@A :? 42D6D 92D 2=D@ =65 E@ 2 D92CA 5C@A :? 9@DA:E2=:K2E:@?D 2?5 562E9D]k^Am

kAm%96 C@==:?8 52:=J 2G6C286 ?F>36C @7 r~'xs\`h A2E:6?ED :? {:?4@=? 9@DA:E2=D H2D ah 2E E96 6?5 @7 =2DE H66<] p?5 E96 4@F?EJ 92D 925 @?=J EH@ 562E9D :? |2C49[ 4@>A2C65 H:E9 ba :? u63CF2CJ 2?5 bh :? y2?F2CJ] %96 =2DE 4@C@?2G:CFD\C6=2E65 562E9 H2D C6A@CE65 ?62C=J EH@ H66<D 28@]k^Am

kAm“(6 92G6 C624965 E9:D >:=6DE@?6 3642FD6 @7 J@F — @FC C6D:56?ED — 2?5 E96 A@D:E:G6 24E:@?D J@F 92G6 E2<6? E@ AC@E64E J@FCD6=7 2?5 @E96CD[” D2:5 |2J@C {6:C:@? v2J=@C q2:C5]k^Am

kAmv2J=@C q2:C5 2=D@ >256 2 A@:?E E@ E92?< E96 AF3=:4 962=E9 E62> 7@C :ED H@C< E9C@F89@FE E96 A2?56>:4[ 96C 6>@E:@?D D9@H:?8 2D D96 D:?8=65 @FE {@A6K 2D Q>J 72G@C:E6 ?FCD6 @7 2== H9@ =65 E96 H2J 7C@> s2J `]Qk^Am

Gaylor Baird

kAm%96 5C2>2E:4 :>AC@G6>6?E :? =@42= 42D6 ?F>36CD >:CC@CD DE2E:DE:4D DE2E6H:56] %@E2= r~'xs\`h 42D6D :? }63C2D<2 =2DE H66< 9:E E96:C =@H6DE =6G6= D:?46 62C=J yF?6[ 244@C5:?8 E@ r6?E6CD 7@C s:D62D6 r@?EC@= 2?5 !C6G6?E:@? 52E2[ 2?5 E96 ``h 9@DA:E2=:K2E:@?D 2D @7 |@?52J ?:89E H6C6 E96 76H6DE D:?46 =2E6 yF=J]k^Am

kAm|@G:?8 E96 =@42= C:D< 5:2= E@ 8C66? :D >@DE=J DJ>3@=:4[ 2D 2== 4@F?EJ\>2?52E65 r~'xs\`h C6DEC:4E:@?D 92G6 2=C625J 366? 6=:>:?2E65]k^Am

kAm%96 C:D< 5:2= C6EFC?:?8 E@ 8C66? H:==[ 9@H6G6C[ >62? D@>6 >:?@C 492?86D 2E E96 &?:G6CD:EJ @7 }63C2D<2\{:?4@=?[ H9:49 H:== 5@ 2H2J H:E9 :ED C6>2:?:?8 >2D< C6BF:C6>6?ED]k^Am

kAm!6@A=6 2C6 DE:== C6BF:C65 E@ H62C >2D<D @? 4:EJ 3FD6D 2?5 @? @E96C 7@C>D @7 AF3=:4 EC2?DA@CE2E:@?[ 2?5 {:?4@=?VD 9@DA:E2=D DE:== C6BF:C6 2== G:D:E@CD E@ H62C >2D<D]k^Am

kAm$:?46 E96 C:D< 5:2= H2D :>A=6>6?E65 :? |2J a_a_[ :E 92D?VE 6?;@J65 >F49 E:>6 :? E96 8C66?] xE 563FE65 :? E96 @C2?86 C2?86 2?5 5:5 ?@E >@G6 :?E@ E96 8C66? 7@C E96 7:CDE E:>6 F?E:= >:5\|2J @7 =2DE J62C[ 2?5 :E DE2J65 E96C6 7@C 2 =:EE=6 >@C6 E92? EH@ >@?E9D]k^Am

kAmw@H =@?8 E96 C:D< 5:2= H:== DE2J :? 8C66? E9:D E:>6 :D 2?J3@5JVD 8F6DD]k^Am

kAmQvC66? :D 2 8C62E A=246 E@ 36[ 2?5 x C62==J H2?E E@ E92?< 6G6CJ@?6 H9@ 96=A65 FD 86E E96C6[Q {@A6K D2:5] Qw@H6G6C[ E96 7FEFC6 4@FCD6 @7 E96 A2?56>:4 C6>2:?D F?46CE2:?]Qk^Am

kAm$96 D2:5 :EVD :>A@CE2?E 7@C 6G6CJ@?6 E@ DE2J 7=6I:3=6 2?5 6IA64E E92E :7 4@?5:E:@?D 492?86[ QH6 H:== C66G2=F2E6 4FCC6?E C64@>>6?52E:@?D 2?5 >2<6 25;FDE>6?ED 2D ?646DD2CJ]Qk^Am

TestNebraska provider says it did more than 1 million COVID-19 tests
Watch Now: Bells toll for 488 Bryan patients lost to COVID-19

kAm{@A6K 2?5 v2J=@C q2:C5 3@E9 C64@>>6?565 E92E A6@A=6 86E G244:?2E65 :7 E96J 92G6?VE J6E 2?5^@C 86E E96:C 3@@DE6C D9@E]k^Am

kAm%9@F89 42D6 4@F?ED 92G6 4@?E:?F65 E@ 5C@A 3@E9 =@42==J 2?5 ?2E:@?2==J[ >2?J 6IA6CED AC65:4E E96 &]$] H:== D66 2?@E96C H2G6 42FD65 3J E96 qp]a DEC2:? @7 E96 @>:4C@? G2C:2?E[ H9:49 92D 42FD65 DFC86D @G6C E96 A2DE 76H H66<D :? 4@F?EC:6D :? pD:2 2?5 tFC@A6]k^Am

kAmp3@FE @?6\E9:C5 @7 42D6D :? E96 &]$] =2DE H66< H6C6 2EEC:3FE65 E@ qp]a[ 244@C5:?8 E@ E96 rsr[ 3FE E96 DEC2:? 244@F?E65 7@C 23@FE 92=7 E96 42D6D :? E96 }@CE962DE]k^Am

kAmp=D@[ >2?J 4:E:6D 92G6 D9@H? FAE:4<D :? E96 2>@F?E @7 G:CFD A2CE:4=6D 7@F?5 :? H2DE6H2E6C D2>A=:?8[ H9:49 :D @7E6? 2 AC64FCD@C E@ 2? :?4C62D6 :? 42D6D]k^Am

kAmsC] tC:4 %@A@=[ 9625 @7 $4C:AAD #6D62C49 %C2?D=2E:@?2= x?DE:EFE6[ D2:5 96 36=:6G6D :EVD :?6G:E23=6 E92E E96 &]$] H:== D66 2? FAE:4< :? 42D6D D@@? 5F6 E@ qp]a]k^Am

kAm“z66A J@FC 8F2C5 FA[” %@A@= D2:5] “%9:D :D ?@E @G6C]”k^Am

kAm%96 8@@5 ?6HD =@42==J :D E92E H2DE6H2E6C >@?:E@C:?8 5@?6 3J {:?4@=? %C2?DA@CE2E:@? 2?5 &E:=:E:6D D@ 72C 92D ?@E D9@H? 2? FAE:4< :? G:C2= A2CE:4=6D[ {@A6K D2:5]k^Am

kAm%96 7:CDE qp]a 42D6 :? {2?42DE6C r@F?EJ H2D C6A@CE65 %F6D52J]k^Am

kAmQ~FC 4@>>F?:EJVD :? 2 36EE6C A=246[ 2E =62DE 7@C ?@H[Q {@A6K D2:5]k^Am

kAmk6>m%96 pDD@4:2E65 !C6DD 4@?EC:3FE65 E@ E9:D C6A@CE]k^6>mk^Am

Nebraska hospitals nearly back to normal thanks to drop in COVID-19 cases

How the availability of COVID-19 treatments has changed throughout the pandemic

How the availability of COVID-19 treatments has changed throughout the pandemic

At the beginning of the COVID-19 pandemic in March 2020, doctors had limited knowledge of how to respond to this new disease. Physicians in hard-hit regions across the world had to learn as they treated the first wave of patients, relying on ventilators and high-flow oxygen treatments, as well as early drugs such as hydroxychloroquine and remdesivir to reduce patients’ risk of dying.

Years later, we have since seen several vaccines prove highly effective in preventing severe disease. The Pfizer/BioNTech, Moderna, and Johnson & Johnson vaccines were all developed in record time, building upon past research into coronavirus vaccines and genetic technology. In December 2021, unvaccinated adults in the U.S. were 2.4 times more likely to test positive for COVID-19 than fully vaccinated adults and were 14 times as likely to die of the disease, according to the Centers for Disease Control and Prevention. The likelihood of unvaccinated infection rose to 2.6 times as recently as January 2022.

At the same time, pharmaceutical companies have developed a variety of drugs that may alleviate COVID-19 symptoms in those who test positive. Monoclonal antibody treatments provide a boost to the immune system, as patients receive infusions of lab-made proteins designed to fight off the coronavirus. In December 2021, the U.S. Food and Drug Administration provided emergency authorization to an antiviral pill treatment that reduces the risk of COVID-19 hospitalization and death. Both the monoclonal antibodies and pills are most effective when patients receive treatment soon after their COVID-19 symptoms begin.

Relative to the fact that this is a novel disease never before known to medical science, progress in treatment development has been remarkably swift and agile. Stacker compiled a list of milestones in the availability of COVID-19 treatments and vaccines throughout the first two years of the pandemic, using information from the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration, and media reports.

faboi // Shutterstock

January 2020: SARS-CoV-2 sequence is made public

The world first learned about the coronavirus in late 2019, as the disease spread through Wuhan, China. Within weeks of the first documented COVID-19 cases, a group of scientists—including those in China and international collaborators—published the virus’ sequence on an open-access site. Virologist Edward Holmes shared a link to the sequence on Twitter, enabling researchers around the world to begin studying the virus.

That early research included vaccine development at Moderna and BioNTech, a German biotechnology company that would soon partner with Pfizer on clinical trials. As both of these companies had previously been working to produce vaccines based on genetic sequences, they were able to quickly adapt their work to the coronavirus. Moderna’s first clinical trial for its vaccine started in March 2020, just two months later.

Smith Collection/Gado // Getty Images

March 2020: Emergency authorization for hydroxychloroquine

In the early months of the pandemic, doctors treating severely ill COVID-19 patients had very little information about what drugs or treatment methods might be most effective. This knowledge gap led some doctors to try out drugs that had not undergone clinical trials for COVID-19, while regulators attempted to provide guidance as quickly as possible.

One drug that became popular during this period was hydroxychloroquine, a drug primarily used to treat malaria and some forms of arthritis and lupus. After some early data suggested hydroxychloroquine might also work against COVID-19, the FDA provided this drug with an Emergency Use Authorization in late March; it was also touted as a potential miracle drug by then-President Donald Trump. Further clinical trials showed that hydroxychloroquine did not actually help alleviate COVID-19 symptoms, however, and the FDA revoked its authorization in June 2020.

Laurent Viteur // Getty Images

May 2020: Emergency authorization for antiviral drug remdesivir

Remdesivir was another early drug that received Emergency Use Authorization in spring 2020. This antiviral drug, made by the biopharmaceutical company Gilead Sciences, was shown to shorten COVID-19 patients’ recovery time in a trial run by the National Institutes of Health. After its emergency authorization, the federal government purchased about 500,000 treatment courses of remdesivir to distribute to U.S. hospitals between June and September 2020.

Later, in 2020, hospitals started working directly with Gilead to purchase the drug. It has remained one of the most widely used antiviral drugs for hospitalized COVID-19 patients and was fully approved by the FDA—a more rigorous process than emergency authorization—in October 2020.

ULRICH PERREY/POOL/AFP // Getty Images

November 2020: First monoclonal antibody treatment receives authorization

Pharmaceutical company Eli Lilly was the first to begin testing a monoclonal antibody treatment for COVID-19. In these treatments, patients receive infusions of lab-made immune system proteins that are designed to fight off the coronavirus. The treatments effectively give a boost to the immune systems of patients who are particularly vulnerable to severe symptoms.

Bamlanivimab, Eli Lilly’s monoclonal antibody treatment, received Emergency Use Authorization from the FDA in November 2020. A similar treatment made by Regeneron received Emergency Authorization later that month. Both treatments were initially only available for high-risk patients in hospitals but became more widely distributed in 2021.

Irfan Khan / Los Angeles Times // Getty Images

December 2020: Pfizer, Moderna vaccines receive authorization

Less than a year after Chinese scientists publicly shared the coronavirus’ genetic sequence, two mRNA vaccines designed from this sequence received emergency authorization from the FDA. Many scientists and health experts considered this quick timeline a “miracle,” as no vaccine had ever been produced so fast in human history.

The Pfizer/BioNTech and Moderna vaccines were able to progress so quickly because both BioNTech and Moderna, along with the National Institutes of Health, had been working on coronaviruses and genetic sequence-based technology for years before COVID-19 hit. In addition, the Trump administration poured billions into vaccine development and production through “Operation Warp Speed,” allowing the COVID-19 vaccines to move through bureaucratic hurdles more efficiently.

The U.S. vaccine rollout started on Dec. 14, 2020, with a New York City critical care nurse receiving the nation’s first dose. Healthcare workers and nursing home residents were first in line for doses, followed by seniors and other immunocompromised and otherwise vulnerable Americans.

SAJJAD HUSSAIN/AFP // Getty Images

Summer 2021: Politicization of monoclonal antibody treatments

As the COVID-19 vaccine rollout progressed in 2021, vaccination became increasingly polarized: As of January 2022, 91% of people who identify as Democrat have received at least one dose of vaccine compared to 63% of people who identify as Republican, according to polling by the Kaiser Family Foundation.

Republican politicians who are hesitant to alienate their bases by encouraging vaccination have instead turned to monoclonal antibody treatments as an alternative option for reducing COVID-19 deaths. During the summer 2021 Delta surge—which primarily hit Southern, Republican-led states where mask mandates also served as a political tipping point—governors in Florida, Texas, and other nearby states set up monoclonal antibody clinics where residents could receive these treatments for free.

By mid-September, just seven states were accounting for 70% of monoclonal antibody orders from the federal government, according to the Department of Health and Human Services. The HHS responded by taking control of monoclonal antibody distribution, making it similar to the distribution system for remdesivir in 2020.

Paul Hennessy/SOPA Images/LightRocket // Getty Images

August 2021: Pfizer vaccine receives full FDA approval

Eight months after Americans started receiving the Pfizer/BioNTech vaccine under Emergency Use Authorization, the FDA fully approved this vaccine. “The public can be very confident that this vaccine meets the high standards for safety, effectiveness, and manufacturing quality the FDA requires of an approved product,” Acting FDA Commissioner Janet Woodcock said in a statement at the time.

Some public health experts hoped that the full FDA approval would help to convince vaccine-hesitant Americans—concerned about the rapid timeline for COVID-19 vaccine development—that Pfizer’s vaccine was entirely safe and effective. However, polling and data analysis afterward found that the full approval had a limited impact on vaccine uptake. Vaccination rates went up slightly in late August 2021 but fell again in September.

Michael Nagle/Xinhua // Getty Images

November 2021: Children ages 5-11 become eligible for vaccination

Millions of parents rejoiced in early November 2021 when the FDA and CDC authorized a version of the Pfizer/BioNTech vaccine for children ages 5 to 11. Enthusiastic parents got their children vaccinated in time for the 2021 holiday season. But overall, uptake in this age group has been low so far, with just over 28% of children in this age group having received at least one vaccine dose as of January 2022.

Meanwhile, parents of the youngest Americans (those under 5 years old) are still waiting on vaccine authorization. In December 2021, Pfizer found that two doses of a low-dose version of its vaccine did not provide a strong immune response in children ages 2 to 4; after initially applying for FDA authorization with two doses while continuing to test a third dose, the company postponed its application in February 2022 to wait for more data.

JEFF KOWALSKY/AFP // Getty Images

December 2021: Two anti-COVID pills receive authorization

As of December 2021, Americans who get infected with the coronavirus now have two options for treatment that do not require infusion in a health care center. The FDA provided emergency authorization to two antiviral treatments in pill form: one produced by Pfizer, the other by Merck.

Both pills work by stalling the coronavirus’ replication in the body, leading to a lower risk of severe symptoms. The Pfizer pill, called Paxlovid, has been much more successful in clinical trials: It reduces the risk of hospitalization and death by 88%, compared to 30% for Merck’s pill. For both treatments, patients must get a prescription and begin taking the pills within five days of onset of COVID-19 symptoms—which can be challenging, as supplies of the drugs are limited in the U.S., as of early 2022.

Jakub Porzycki/NurPhoto // Getty Images

February 2022: Eli Lilly develops new monoclonal antibody treatment for Omicron

The Omicron variant caused a major shift in COVID-19 treatment availability, as scientists at Eli Lilly and Regeneron quickly discovered that their monoclonal antibody drugs no longer worked well against this version of the virus. Consequently, the FDA limited its emergency authorization for their use. Nonetheless, some of the same Southern states that popularized these drugs in summer 2021 continued to provide them during the Omicron surge despite their ineffectiveness.

Eli Lilly responded to the situation by developing a new monoclonal antibody treatment, called bebtelovimab, that is effective against Omicron. According to the company, this new drug also works against BA.2, a sister lineage of Omicron that has garnered some concern as it is even more contagious than Omicron itself. The U.S. government has purchased 600,000 courses of bebtelovimab, to be distributed in February and March 2022.

Jonathan Weiss // Shutterstock

Reach the writer at 402-473-2647 or molberding@journalstar.com.

On Twitter @LincolnBizBuzz.

0 Comments

Love

0

Funny

0

Wow

0

Sad

0

Angry

0

Be the first to know

Get local news delivered to your inbox!

Sign up!

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

MattOlberding

Matt Olberding

Follow Matt Olberding

Close

Get email notifications on {{subject}} daily!

Your notification has been saved.

There was a problem saving your notification.

{{description}}

Email notifications are only sent once a day, and only if there are new matching items.

Save

Manage followed notifications

Close

Followed notifications

Please log in to use this feature

Log In

Don't have an account? Sign Up Today

Related to this story

Nomi Health to offer free mental health care to front-line health care workers in Nebraska

Nomi Health will offer $1 million in free behavioral health care to front-line health care workers in Nebraska and a handful of other states b…

Watch now: Bryan official follows through on pandemic pledge to get inked

Bob Ravenscroft promised to get a tattoo after Iron Brush Tattoo donated 29,000 surgical gloves in March 2020. Earlier this month, he followed…

Planned Parenthood group covering Nebraska and Iowa gets $20 million gift

Planned Parenthood North Central States, which includes Nebraska and Iowa, has received $20 million from philanthropist MacKenzie Scott.

Lincoln man recovering from COVID-19 makes point to thank those who helped him

Jeff Walker spent 87 days in various hospitals and did two stints on a ventilator at CHI Health St. Elizabeth. He wanted to acknowledge those …

Nebraska's COVID-related hospitalizations continue to decline

The state reported a negative number of cases for the week to the CDC. Nebraska health officials said the negative number is a result of effor…

Lincoln continuing to see positive trend on COVID-19

Cases and hospitalizations both continue to decline, but health experts say they are concerned it's only matter of time until the BA.2 variant…

Nebraska among states challenging CDC transit mask rule

The lawsuit, filed in federal court in Tampa, Florida, contends that the mask mandate exceeds the authority of the U.S. Centers for Disease Co…

COVID-19 case numbers remain steady in Lincoln

Cases fell slightly last week compared with the previous week, but hospitalizations have risen slightly.

Close

Leirion Gaylor Baird

Gaylor Baird

Lopez

×

JournalStar.com

Prefer us on Google Learn More

Sites & Partners

Services

© Copyright 2026 The Lincoln Journal Star, PO Box 81609 Lincoln, NE 68501

A Lee Enterprises, Incorporated newspaper. Majority shareholder: David Hoffmann, Hoffmann Media Group.

Terms of Use | Privacy Policy | Advertising Terms of Use | Privacy Choices | Cookie Preferences

Powered by BLOX Content Management System from bloxdigital.com.

{{title}}

{{summary}}

You don't have any notifications.

Get up-to-the-minute news sent straight to your device.

Topics

News Alerts

Subscribe

Breaking News

Subscribe

Husker News

Subscribe

VisaMastercardAmerican ExpressDiscoverJCBDiners ClubCredit CardCredit Card

Back ×

Offer

Sorry, an error occurred.

Already Subscribed!

Get StartedManage Service

Cancel anytime

You are logged in

 Switch accounts

Secure transaction. Cancel anytime. Have an account? Log In

Back ×

Sign Up

Account processing issue - the email address may already exist

User information

Username (Optional)

This is the name that will be displayed next to your photo for comments, blog posts, and more. Choose wisely!

* First name

* Last name

* Email Address

Your email address will be used to confirm your account. We won't share it with anyone else.

* Password

Must be at least 8 characters, not contain repeating characters (e.g., 111), and not contain sequential numbers (e.g., 123).

Create a password that only you will remember. If you forget it, you'll be able to recover it using your email address.

* Confirm Password

Confirm your password.

CAPTCHA

Create Account

or

Sign up with

Facebook Google

Have an account? Log In

×

You're all set!

Thank you .

Your account has been registered, and you are now logged in.

Check your email for details.

OK

Back ×

Log In

Invalid password or account does not exist

Email Address

Password

Remember me

Forgot your password?

Log In

Email me a log in link

or

Sign in with

Facebook Google

Admin login Subscribe

Need an account? Sign Up

Back ×

Reset Password

Submitting this form below will send a message to your email with a link to change your password.

Email or Screen Name

CAPTCHA

Reset Password

×

Forgot Password

An email message containing instructions on how to reset your password has been sent to the email address listed on your account.

Back ×

Email me a log in link

Account Email

CAPTCHA

Send Email

Back ×

Promotional Offers

Promo code

Enter Promo Code

Redeem

No promotional rates found.

Back ×

Purchase Gift Purchase Access

See More Offers

details close

×

An error occurred

×

Secure & Encrypted

Sign in with

Email Address

Continue with Email Address

or

Continue with Facebook Continue with Google

What's your email address?

Email

Password

Confirm password

Must be at least 8 characters, not contain repeating characters (e.g., 111), and not contain sequential numbers (e.g., 123).

What's your name?

First name

Last name

Who is this gift for?

Recipient name

Recipient email

Optional message for the recipient

Who is this gift from?

Purchaser name

Purchaser email

Purchaser zip code

Delivery date

Delivery date

What's your billing location?

Address

City

State AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWashington D.C.West VirginiaWisconsinWyomingPuerto RicoUS Virgin IslandsArmed Forces AmericasArmed Forces PacificArmed Forces EuropeNorthern Mariana IslandsMarshall IslandsAmerican SamoaFederated States of MicronesiaGuamPalauAlberta, CanadaBritish Columbia, CanadaManitoba, CanadaNew Brunswick, CanadaNewfoundland, CanadaNova Scotia, CanadaNorthwest Territories, CanadaNunavut, CanadaOntario, CanadaPrince Edward Island, CanadaQuebec, CanadaSaskatchewan, CanadaYukon Territory, Canada

Zip Code

Country United States of AmericaUS Virgin IslandsUnited States Minor Outlying IslandsCanadaMexico, United Mexican StatesBahamas, Commonwealth of theCuba, Republic ofDominican RepublicHaiti, Republic ofJamaicaAfghanistanAlbania, People's Socialist Republic ofAlgeria, People's Democratic Republic ofAmerican SamoaAndorra, Principality ofAngola, Republic ofAnguillaAntarctica (the territory South of 60 deg S)Antigua and BarbudaArgentina, Argentine RepublicArmeniaArubaAustralia, Commonwealth ofAustria, Republic ofAzerbaijan, Republic ofBahrain, Kingdom ofBangladesh, People's Republic ofBarbadosBelarusBelgium, Kingdom ofBelizeBenin, People's Republic ofBermudaBhutan, Kingdom ofBolivia, Republic ofBosnia and HerzegovinaBotswana, Republic ofBouvet Island (Bouvetoya)Brazil, Federative Republic ofBritish Indian Ocean Territory (Chagos Archipelago)British Virgin IslandsBrunei DarussalamBulgaria, People's Republic ofBurkina FasoBurundi, Republic ofCambodia, Kingdom ofCameroon, United Republic ofCape Verde, Republic ofCayman IslandsCentral African RepublicChad, Republic ofChile, Republic ofChina, People's Republic ofChristmas IslandCocos (Keeling) IslandsColombia, Republic ofComoros, Union of theCongo, Democratic Republic ofCongo, People's Republic ofCook IslandsCosta Rica, Republic ofCote D'Ivoire, Ivory Coast, Republic of theCyprus, Republic ofCzech RepublicDenmark, Kingdom ofDjibouti, Republic ofDominica, Commonwealth ofEcuador, Republic ofEgypt, Arab Republic ofEl Salvador, Republic ofEquatorial Guinea, Republic ofEritreaEstoniaEthiopiaFaeroe IslandsFalkland Islands (Malvinas)Fiji, Republic of the Fiji IslandsFinland, Republic ofFrance, French RepublicFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabon, Gabonese RepublicGambia, Republic of theGeorgiaGermanyGhana, Republic ofGibraltarGreece, Hellenic RepublicGreenlandGrenadaGuadaloupeGuamGuatemala, Republic ofGuinea, Revolutionary People's Rep'c ofGuinea-Bissau, Republic ofGuyana, Republic ofHeard and McDonald IslandsHoly See (Vatican City State)Honduras, Republic ofHong Kong, Special Administrative Region of ChinaHrvatska (Croatia)Hungary, Hungarian People's RepublicIceland, Republic ofIndia, Republic ofIndonesia, Republic ofIran, Islamic Republic ofIraq, Republic ofIrelandIsrael, State ofItaly, Italian RepublicJapanJordan, Hashemite Kingdom ofKazakhstan, Republic ofKenya, Republic ofKiribati, Republic ofKorea, Democratic People's Republic ofKorea, Republic ofKuwait, State ofKyrgyz RepublicLao People's Democratic RepublicLatviaLebanon, Lebanese RepublicLesotho, Kingdom ofLiberia, Republic ofLibyan Arab JamahiriyaLiechtenstein, Principality ofLithuaniaLuxembourg, Grand Duchy ofMacao, Special Administrative Region of ChinaMacedonia, the former Yugoslav Republic ofMadagascar, Republic ofMalawi, Republic ofMalaysiaMaldives, Republic ofMali, Republic ofMalta, Republic ofMarshall IslandsMartiniqueMauritania, Islamic Republic ofMauritiusMayotteMicronesia, Federated States ofMoldova, Republic ofMonaco, Principality ofMongolia, Mongolian People's RepublicMontserratMorocco, Kingdom ofMozambique, People's Republic ofMyanmarNamibiaNauru, Republic ofNepal, Kingdom ofNetherlands AntillesNetherlands, Kingdom of theNew CaledoniaNew ZealandNicaragua, Republic ofNiger, Republic of theNigeria, Federal Republic ofNiue, Republic ofNorfolk IslandNorthern Mariana IslandsNorway, Kingdom ofOman, Sultanate ofPakistan, Islamic Republic ofPalauPalestinian Territory, OccupiedPanama, Republic ofPapua New GuineaParaguay, Republic ofPeru, Republic ofPhilippines, Republic of thePitcairn IslandPoland, Polish People's RepublicPortugal, Portuguese RepublicPuerto RicoQatar, State ofReunionRomania, Socialist Republic ofRussian FederationRwanda, Rwandese RepublicSamoa, Independent State ofSan Marino, Republic ofSao Tome and Principe, Democratic Republic ofSaudi Arabia, Kingdom ofSenegal, Republic ofSerbia and MontenegroSeychelles, Republic ofSierra Leone, Republic ofSingapore, Republic ofSlovakia (Slovak Republic)SloveniaSolomon IslandsSomalia, Somali RepublicSouth Africa, Republic ofSouth Georgia and the South Sandwich IslandsSpain, Spanish StateSri Lanka, Democratic Socialist Republic ofSt. HelenaSt. Kitts and NevisSt. LuciaSt. Pierre and MiquelonSt. Vincent and the GrenadinesSudan, Democratic Republic of theSuriname, Republic ofSvalbard & Jan Mayen IslandsSwaziland, Kingdom ofSweden, Kingdom ofSwitzerland, Swiss ConfederationSyrian Arab RepublicTaiwan, Province of ChinaTajikistanTanzania, United Republic ofThailand, Kingdom ofTimor-Leste, Democratic Republic ofTogo, Togolese RepublicTokelau (Tokelau Islands)Tonga, Kingdom ofTrinidad and Tobago, Republic ofTunisia, Republic ofTurkey, Republic ofTurkmenistanTurks and Caicos IslandsTuvaluUganda, Republic ofUkraineUnited Arab EmiratesUnited Kingdom of Great Britain & N. IrelandUruguay, Eastern Republic ofUzbekistanVanuatuVenezuela, Bolivarian Republic ofViet Nam, Socialist Republic ofWallis and Futuna IslandsWestern SaharaYemenZambia, Republic ofZimbabwe

What's your delivery address?

Copy billing location

Address

City

State AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWashington D.C.West VirginiaWisconsinWyomingPuerto RicoUS Virgin IslandsArmed Forces AmericasArmed Forces PacificArmed Forces EuropeNorthern Mariana IslandsMarshall IslandsAmerican SamoaFederated States of MicronesiaGuamPalauAlberta, CanadaBritish Columbia, CanadaManitoba, CanadaNew Brunswick, CanadaNewfoundland, CanadaNova Scotia, CanadaNorthwest Territories, CanadaNunavut, CanadaOntario, CanadaPrince Edward Island, CanadaQuebec, CanadaSaskatchewan, CanadaYukon Territory, Canada

Zip code

Country

United States of AmericaUS Virgin IslandsUnited States Minor Outlying IslandsCanadaMexico, United Mexican StatesBahamas, Commonwealth of theCuba, Republic ofDominican RepublicHaiti, Republic ofJamaicaAfghanistanAlbania, People's Socialist Republic ofAlgeria, People's Democratic Republic ofAmerican SamoaAndorra, Principality ofAngola, Republic ofAnguillaAntarctica (the territory South of 60 deg S)Antigua and BarbudaArgentina, Argentine RepublicArmeniaArubaAustralia, Commonwealth ofAustria, Republic ofAzerbaijan, Republic ofBahrain, Kingdom ofBangladesh, People's Republic ofBarbadosBelarusBelgium, Kingdom ofBelizeBenin, People's Republic ofBermudaBhutan, Kingdom ofBolivia, Republic ofBosnia and HerzegovinaBotswana, Republic ofBouvet Island (Bouvetoya)Brazil, Federative Republic ofBritish Indian Ocean Territory (Chagos Archipelago)British Virgin IslandsBrunei DarussalamBulgaria, People's Republic ofBurkina FasoBurundi, Republic ofCambodia, Kingdom ofCameroon, United Republic ofCape Verde, Republic ofCayman IslandsCentral African RepublicChad, Republic ofChile, Republic ofChina, People's Republic ofChristmas IslandCocos (Keeling) IslandsColombia, Republic ofComoros, Union of theCongo, Democratic Republic ofCongo, People's Republic ofCook IslandsCosta Rica, Republic ofCote D'Ivoire, Ivory Coast, Republic of theCyprus, Republic ofCzech RepublicDenmark, Kingdom ofDjibouti, Republic ofDominica, Commonwealth ofEcuador, Republic ofEgypt, Arab Republic ofEl Salvador, Republic ofEquatorial Guinea, Republic ofEritreaEstoniaEthiopiaFaeroe IslandsFalkland Islands (Malvinas)Fiji, Republic of the Fiji IslandsFinland, Republic ofFrance, French RepublicFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabon, Gabonese RepublicGambia, Republic of theGeorgiaGermanyGhana, Republic ofGibraltarGreece, Hellenic RepublicGreenlandGrenadaGuadaloupeGuamGuatemala, Republic ofGuinea, Revolutionary People's Rep'c ofGuinea-Bissau, Republic ofGuyana, Republic ofHeard and McDonald IslandsHoly See (Vatican City State)Honduras, Republic ofHong Kong, Special Administrative Region of ChinaHrvatska (Croatia)Hungary, Hungarian People's RepublicIceland, Republic ofIndia, Republic ofIndonesia, Republic ofIran, Islamic Republic ofIraq, Republic ofIrelandIsrael, State ofItaly, Italian RepublicJapanJordan, Hashemite Kingdom ofKazakhstan, Republic ofKenya, Republic ofKiribati, Republic ofKorea, Democratic People's Republic ofKorea, Republic ofKuwait, State ofKyrgyz RepublicLao People's Democratic RepublicLatviaLebanon, Lebanese RepublicLesotho, Kingdom ofLiberia, Republic ofLibyan Arab JamahiriyaLiechtenstein, Principality ofLithuaniaLuxembourg, Grand Duchy ofMacao, Special Administrative Region of ChinaMacedonia, the former Yugoslav Republic ofMadagascar, Republic ofMalawi, Republic ofMalaysiaMaldives, Republic ofMali, Republic ofMalta, Republic ofMarshall IslandsMartiniqueMauritania, Islamic Republic ofMauritiusMayotteMicronesia, Federated States ofMoldova, Republic ofMonaco, Principality ofMongolia, Mongolian People's RepublicMontserratMorocco, Kingdom ofMozambique, People's Republic ofMyanmarNamibiaNauru, Republic ofNepal, Kingdom ofNetherlands AntillesNetherlands, Kingdom of theNew CaledoniaNew ZealandNicaragua, Republic ofNiger, Republic of theNigeria, Federal Republic ofNiue, Republic ofNorfolk IslandNorthern Mariana IslandsNorway, Kingdom ofOman, Sultanate ofPakistan, Islamic Republic ofPalauPalestinian Territory, OccupiedPanama, Republic ofPapua New GuineaParaguay, Republic ofPeru, Republic ofPhilippines, Republic of thePitcairn IslandPoland, Polish People's RepublicPortugal, Portuguese RepublicPuerto RicoQatar, State ofReunionRomania, Socialist Republic ofRussian FederationRwanda, Rwandese RepublicSamoa, Independent State ofSan Marino, Republic ofSao Tome and Principe, Democratic Republic ofSaudi Arabia, Kingdom ofSenegal, Republic ofSerbia and MontenegroSeychelles, Republic ofSierra Leone, Republic ofSingapore, Republic ofSlovakia (Slovak Republic)SloveniaSolomon IslandsSomalia, Somali RepublicSouth Africa, Republic ofSouth Georgia and the South Sandwich IslandsSpain, Spanish StateSri Lanka, Democratic Socialist Republic ofSt. HelenaSt. Kitts and NevisSt. LuciaSt. Pierre and MiquelonSt. Vincent and the GrenadinesSudan, Democratic Republic of theSuriname, Republic ofSvalbard & Jan Mayen IslandsSwaziland, Kingdom ofSweden, Kingdom ofSwitzerland, Swiss ConfederationSyrian Arab RepublicTaiwan, Province of ChinaTajikistanTanzania, United Republic ofThailand, Kingdom ofTimor-Leste, Democratic Republic ofTogo, Togolese RepublicTokelau (Tokelau Islands)Tonga, Kingdom ofTrinidad and Tobago, Republic ofTunisia, Republic ofTurkey, Republic ofTurkmenistanTurks and Caicos IslandsTuvaluUganda, Republic ofUkraineUnited Arab EmiratesUnited Kingdom of Great Britain & N. IrelandUruguay, Eastern Republic ofUzbekistanVanuatuVenezuela, Bolivarian Republic ofViet Nam, Socialist Republic ofWallis and Futuna IslandsWestern SaharaYemenZambia, Republic ofZimbabwe

Phone

Purchase detail

Subtotal:

Total:

How would you like to pay?

Ending in

Add New Card

American Express Discover Mastercard Visa JCB Diners Club Credit Card Credit Card

Terms of service confirmation

I Agree to the Subscription Terms of Use.
This service will be automatically renewed and your credit card billed once it nears expiration.

Secure transaction. Secure transaction. Cancel anytime.

×

You're all set!

Thank you.

Your gift purchase was successful! Your purchase was successful, and you are now logged in.

Rate: Begins: Transaction ID:

A receipt was sent to your email.

OK

×

An error occurred

This offer is currently unavailable.

Close

Search AI Answers